methylene blue/vitamin C/N-acetyl cysteine (leucomethylene Blue) / Mashhad University of Medical Sciences - LARVOL DELTA

The Potential of Leucomethylene Blue in Methemoglobinemia Treatment: A New Hope for Patients with G6PD? (PubMed, Curr Med Chem) - "LMB can even be administrated in other treatments without any concern about increasing oxidative stress, exacerbating the inflammation. Proof-of-concept experimental and clinical trials could substantiate this hypothesis."

Journal • Hematological Disorders • Inflammation • Metabolic Disorders

Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. (PubMed, Eur J Pharmacol) - "Nitrite, nitrate (the metabolites of NO), methemoglobin, and prooxidant-antioxidant-balance levels were measured in 25 ICU COVID-19 patients and 25 healthy individuals. As the last therapeutic option, five patients were administered methylene blue-vitamin C-N-acetyl Cysteine (MCN). Nitrite, nitrate, methemoglobin, and oxidative stress were significantly increased in patients in comparison to healthy individuals. Four of the five patients responded well to treatment....NO, methemoglobin and oxidative stress may play a central role in the pathogenesis of critical COVID-19 disease. MCN treatment seems to increase the survival rate of these patients."

Clinical • Journal • P1 data • Infectious Disease • Novel Coronavirus Disease

Clinical Application of Methylene Blue for Treatment of Covid-19 Patients (clinicaltrials.gov) - P1; N=20; Recruiting; Sponsor: Mashhad University of Medical Sciences

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease